McMillan Wayde D. 4

What Happened Wayde D. McMillan, a director of Hologic, Inc. (HOLX), received an award of 3,190 restricted stock units (RSUs) on 2026-02-26. The filing lists the grant as an "A" (award/acquisition) with no per-share price reported (N/A); these RSUs will settle in common stock on a one-for-one basis when they vest. This is a compensation grant (not a market purchase or sale), so it is not an immediate buy/sell market signal.

Key Details

• Transaction date: 2026-02-26; Form 4 filed: 2026-03-02 (Accession 0000859737-26-000023). Filing appears timely under Form 4 rules.
• Grant: 3,190 restricted stock units; price: N/A; total cash value not disclosed in the Form 4.
• Vesting/settlement: RSUs vest on the date of the 2027 Annual Meeting of Stockholders (Footnote F1) and are settled in shares on a one-for-one basis (Footnote F2).
• Shares owned after transaction: not specified in the provided transaction details.
• No 10b5-1 plan, tax-withholding sale, or sale/exercise reported in this filing excerpt.

Context RSU grants to board members are common as part of compensation and typically vest in the future; they should not be read as an immediate purchase or sale of stock. Because these units convert to shares at vesting, they will dilute share count modestly when settled, but the grant itself does not involve an open-market transaction.